Theranostic 64Cu-DOTHA2-PSMA for metastatic prostate cancer treatment, a preclinical study

被引:0
|
作者
Milot, M. C. [1 ]
Benesty, O. Belissant [1 ]
Dumulon-Perreault, V. [2 ]
Ait-Mohand, S. [1 ]
Rousseau, E. [1 ]
Richard, P. [3 ]
Guerin, B. [1 ]
机构
[1] Univ Sherbrooke, Nucl Med & Radiobiol, Sherbrooke, PQ, Canada
[2] CRCHUS, Ctr Imagerie Mole Sherbrooke, Sherbrooke, PQ, Canada
[3] Univ Sherbrooke, Surg, Sherbrooke, PQ, Canada
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
56
引用
收藏
页码:S24 / S24
页数:1
相关论文
共 50 条
  • [1] 64Cu-DOTHA2-PSMA, a novel theranostic agent for prostate cancer and its preclinical animal evaluation
    Milot, Marie-Christine
    Benesty, Ophelie Belissant
    Dumulon-Perreault, Veronique
    Ait-Mohand, Samia
    Rousseau, Etienne
    Richard, Patrick
    Guarin, Brigitte
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 96-97 : S105 - S105
  • [2] A stronger chelation for a superior theranostic : the preclinical study of 64Cu-DOTHA2-PSMA in prostate cancer animal model
    Milot, Marie-Christine
    Benesty, Ophelie Belissant
    Dumulon-Perreault, Veronique
    Ait-Mohand, Samia
    Rousseau, Etienne
    Richard, Patrick
    Guerin, Brigitte
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [3] Theranostic 64Cu-DOTHA2-PSMA allows low toxicity radioligand therapy in mice prostate cancer model
    Milot, Marie-Christine
    Belissant-Benesty, Ophelie
    Dumulon-Perreault, Veronique
    Ait-Mohand, Samia
    Geha, Sameh
    Richard, Patrick O. O.
    Rousseau, Etienne
    Guerin, Brigitte
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [4] 64Cu-DOTHA2-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time Window
    Milot, Marie-Christine
    Benesty, Ophelie Belissant
    Dumulon-Perreault, Veronique
    Ait-Mohand, Samia
    Richard, Patrick O.
    Rousseau, Etienne
    Guerin, Brigitte
    PHARMACEUTICALS, 2022, 15 (08)
  • [5] A Cu-64/Cu-67 bifunctional PSMA ligand as a theranostic for prostate cancer
    McInnes, Lachlan
    Zia, Nicholas
    Cullinane, Carleen
    Van Zuylekom, Jessica
    Jackson, Susan
    Stoner, Jon
    Haskali, Mohammad
    Roselt, Peter
    Van Dam, Ellen
    Harris, Matthew
    Hicks, Rodney
    Donnelly, Paul
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [6] A Comparison of 18F-PSMA-1007 and 64Cu-PSMA in 2 Patients With Metastatic Prostate Cancer
    Cardoza-Ochoa, David R.
    Rivera-Bravo, Belen
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (02) : E120 - E122
  • [7] Preclinical evaluation of 64Cu-DOTHA2-FAPI for PET Imaging of head and neck cancer
    Ben-Salem, I.
    Croteau, E.
    Dumulon-Perreault, V.
    Saidi, N.
    Sarrhini, O.
    Ait-Mohand, S.
    Belissant, O.
    Turcotte, E.
    Oweida, A.
    Guerin, B.
    Rousseau, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S448 - S449
  • [8] Preclinical evaluation and frst in human study of 64Cu-PSMA-3Q for prostate cancer imaging
    Zhang, Jingfeng
    Xu, Baixuan
    Zhang, Jinming
    Zhang, Xiaojun
    Liu, Yachao
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [9] Cu-64 PSMA PET in Prostate Cancer
    Mirzaei, S.
    Grubmueller, B.
    Capasso, E.
    Knoll, P.
    Floth, A.
    Meleddu, C.
    Shariat, S.
    Klingler, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S675 - S675
  • [10] A Next Generation Theranostic PSMA Ligand for 64Cu and 67Cu-Based Prostate Cancer Imaging and Therapy
    Ponnala, Shashikanth
    Amor-Coarasa, Alejandro
    Kelly, James
    Zia, Nicholas
    Clarence, Williams
    Nikolopoulou, Anastasia
    Donnelly, Paul
    Babich, John
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60